Tempest Therapeutics, Inc. · NASDAQ:TPST
Tempest Therapeutics — Investor Presentation (May 2026)
23 slides from Tempest Therapeutics's investor presentation, May 6, 2026
Slide 1: Developing Advanced Therapies for Cancer Patients
® Developing Advanced Therapies for Cancer Patients
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) concerning Tempest Therapeutics, Inc. (“T
Slide 3: Partner-Funded Development Driving Diversified Pipeline with Capital Discipline
Partner-Funded Development Driving Diversified Pipeline with Capital Discipline Enables de-risked, data-driven deployment of internal capital DEVELOPMENT STAGE! TPST-2003 Novain ©19/2CMA Dual CART 5 TPST-2206 aan & (6070/0070 Dual CART 9g f \ = TPST-3003 = FEN Universal(Alogenei)CO19/B0MA Dual CART
Slide 4: Selected Potential Value-Inflecting Milestones through Q4 2027
Selected Potential Value-Inflecting Milestones through Q4 2027 2026 2027 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Phase 1/2 IIT REDEEM-1 Phase 2b (China TPST-2003 results and Phase 2a registrational) REDEEM-1 Tech transfer enrollment start Phase 2b (China) CD19/BCMA Dual CAR-T Phase 2b (U.S. Phase 1/2a enrollment st
Slide 5: Targeting CD19/BCMA CAR-T
TPST-2003 Dual Targeting CD19/BCMA CAR-T
Slide 6: CD19/BCMA CAR-T TPST-2003 is the world's first parallel-structure dual-target CAR-T
TPST-2003 CD19/BCMA CAR-T TPST-20031,2 is the world’s first parallel-structure dual-target CAR-T cell therapy for rrMM with EMD & POEMS syndrome • REDEEM-1 Phase 1/2a (rrMM) and POEMS-1 Phase 1 (POEMS syndrome) Dual-target CAR-T structure • 44 patient target – 32 in REDEEM-1 and 12 in POEMS-1 • 20 p
Slide 7: CD19/BCMA Dual Targeting
TPST-2003 Dual CAR-T for rrMM1: CD19/BCMA Dual Targeting 1 Dual-target Mitigate antigen escape © Significantly inhibits tumor growth in CDX model 1 Parallel structure Ensure stable expression of dual targets @ high levels of cytokine release 1 CD28 co-stimulatory domain mutation reduces CAR-T cell e
Slide 8: Study Design
TPST-2003 Dual CAR-T for rrMM1: Study Design Multicenter, open label, IIT study FPI Jan.2021, LPI Jun.2024, Patients continued to be assessed for response Data cut-off Jul.25th,2024, Efficacy evaluable patients N=23, Safety Set N=20, PKPS N=20 Key Inclusion criteria Primary endpoint: Dose Level: • R
Slide 9: Baseline Characteristics
TPST-2003 Dual CAR-T for rrMM1: Baseline Characteristics Baseline Characteristics Total {N=23) Baseline Characteristics Total {N=23) Median age Crange ) 64 (52-77) Median prior lines of therapy, n(%) 5 (2-11) Male, n(%) 12 (52.2) Prior auto-SCT, n(%) 9 (39.1) ECOG performance-status score, n(%) Refr
Slide 10: Hematological Response
TPST-2003 Dual CAR-T for rrMM1: Hematological Response 01003 Hematological ORR* N=18 1 [ 02003 DL N=3 N=10 N=5 N=18 N=3 100% 02002 80% 01010 -02008 ~ 60% - 0 01011 CJ) 40% 0:: sCR 02011 20% 33.30% DL2 02015 CR N=11 0% 02013 1//////////////////////// ....... VGPR DL1 DL2 DL3 All Pts 02017 ¦ VGPR ¦ sC
Slide 11: rrMM: EMD Patient Baseline Characteristics
TPST-2003 Dual CAR-T for rrMM": EMD Patient Baseline Characteristics Baseline Characteristics Total (N=14) Baseline Characteristics Total (N=14) Median age (range) 60 (54-73) Median prior lines of therapy (range) 6 (2-11) Male, n(%) 5357) Prior auto-SCT, n(%) 5 (35.7) ECOG performance-status score R
Slide 12: EMD PET Response
TPST-2003 Dual CAR-T for rrMM1: EMD PET Response Hematological PET Response Of EMD Response PET ORR: 85.7% (12/14) N=1 N=7 N=6 N=14 DL1[ 02003—100% 02008—80% 02015—•••► 02013 0 -;,12_ 60% DL2 Cl) 02017 0.... 40% CMR 02020 PMR 20% 02019 •••► 02021 SMD 0% 02018 Hematologic PD DL 1 DL2 DL3 All Pts •••►
Slide 13: EMD PET Response Cases
TPST-2003 Dual CAR-T for rrMM1: EMD PET Response Case-02008 58-yo male Penta-refractory, 11 prior LOT Case-02003 55-yo female Quad-refractory, 5 prior LOT M3: VGPR & PMR -c, M6: sCR MRD- & CMR for 21 + mos M3: VGPR & CMR-c, M9: sCR MRD- & CMR for 23+ mos 1Jiang, H., et. al. “A Prospective Investigat
Slide 14: Survival
TPST-2003 Dual CAR-T for rrMM1: Survival All EMO NonEJ.,D 100% 100% ~ 15% li 111, ~· 2’ ~ 50%, iii, 2 > ;;;J, (I), ,5~ staVmelfian=23.1(95%ct 13.7--:W,,) E:M D: ::::;u ( 9 s • 1: 6.a- ) NOfl- EM D : S.6 ( 9511GI : :?.07—) 0% 0% 0 3 6 9 2 15 18 21 24 21 30 0 3 6 9 12 5 18 21 21 30 ·me, (month) EMD im
Slide 15: Safety Profile
TPST-2003 Dual CAR-T for rrMM1: Safety Profile TEAEs1 TEAEs TRAEs TRAEs N=20 CRS2 (n,%) ICANS (n,%) N=20 (n,%) Gr~ 3 (n,%) (n,%) Gr~ 3 (n,%) Grade 1-2 17 (85.0) 3 (15.0) Hematologic (TEAEs ~ 5% All Grades) Grade 3 1 (5.0) 2 (10.0) Leukopenia 17(85.0) 14(70.0) 16(80.0) 12(60.0) Thrombocytopenia 17(85
Slide 16: Expansion and Persistence
TPST-2003 Dual CAR-T for rrMM1: Expansion and Persistence CAR-T cell positivity rate-time plot-BCMA+ (PKPS) CAR-T cell VCN-time plot (PKPS) 270000 90 <( 250000 ~ 230000 80 Cl 210000 :::1. ~ ~ 70 ui 190000 u QI 00 60 ‘ii 170000 2 8 150000 ~ so ~ ai 130000 1 40 ‘iii i 110000 \ 0 a. 30 ~ 90000 \ ai >,
Slide 17: rrMM: Conclusions
TPST-2003 Dual CAR-T for rrMM: Conclusions TPST-20031,2 is the world’s first parallel-structure dual-target CAR-T cell therapy for rrMM with EMD & POEMS syndrome • REDEEM-1 Phase 1/2a (rrMM) and POEMS-1 Phase 1 (POEMS syndrome) • 44 patient target – 32 in REDEEM-1 and 12 in POEMS-1 • 20 patients dos
Slide 18: Shows Similar Favorable Safety Profile to Approved BCMA CAR-T
TPST-2003 Shows Similar Favorable Safety Profile to Approved BCMA CAR-T TPST-20031 Abecma Carvykti (BMS)2 (J&J/Legend)3 Target CD19, BCMA BCMA BCMA Stage REDEEM-1 Phase 1/2a Approval Approval Indication rrMM rrMM rrMM Target Dose 1x106 cells/kg 2x106 cells/kg 3x106 cells/kg 420x106 cells 0.75x106 ce
Slide 19: Performance Relative to Approved Therapies
TPST-2003 Performance Relative to Approved Therapies TPST-20031 Abecma Carvykti (BMS)2 (J&J/Legend)3 Target CD19, BCMA BCMA BCMA Stage Phase 1/2 IIT Approval Approval Indication rrMM rrMM rrMM KarMMa CARTITUDE-1 Trial IIT (NCT 03361748) (NCT 03548207) Number of 15 50 19 EMD patients Median PFS of EM
Slide 20: Small Molecule Programs
Small Molecule Programs Amezalpat (TPST-1120) First-in-Class PPAR�� Antagonist TPST-1495 First-in-Class Dual EP2/4 Antagonist
Slide 21: Amezalpat Improved All Efficacy Endpoints vs. SoC Control in Global HCC Phase 2
Amezalpat Improved All Efficacy Endpoints vs. SoC Control in Global HCC Phase 2 Primary Global Regulatory an ‘S TEMPEST atezolbev ‘TPST-1120 + atezolbev N=30 N=40 15m 211 > HR 0.65 PFS HROS Median 4.27m (2.8, 7.3) 7m (5.6, 13.8) Consistent Improvement Confirmed ORR (ITT population) 13.3% 30% Across
Slide 22: TPST-1495 is a First-in-Class Dual EP2/EP4 PGE2 Receptor Antagonist
TPST-1495 is a First-in-Class! Dual EP2/EP4 PGE2 Receptor Antagonist TPST-1495 therapy conferred a significant survival advantage compared to other prostaglandin pathway inhibitors Therapeutic activity comparison in Apc!" mouse model of FAP Tumor burden after 3 weoks of, Survival ator 3 wooks of the
Slide 23: Developing Advanced Therapies for Cancer Patients
® Developing Advanced Therapies for Cancer Patients May 6, 2026
Tempest Therapeutics — Investor Presentation (May 2026) on 6ix